Pharmacokinetics of linezolid in subjects with renal dysfunction

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 9, 2003, Pages 2775-2780

  Brier, Michael E ^a,b   Stalker, Dennis J ^c   Aronoff, George R ^a   Batts, Donald H ^c   Ryan, Kristi K ^c   O'Grady, Margaret ^a   Hopkins, Nancy K ^c   Jungbluth, Gail L ^c  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACETAMIDES; ADULT; AGED; ANTI-BACTERIAL AGENTS; CREATININE; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; OXAZOLIDINONES; RENAL DIALYSIS;

EID: 0042925335     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.9.2775-2780.2003     Document Type: Article

References (13)

1. Chien, J. W., M. L. Kucia, and R. A. Salata. 2000. Use ot linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infection. Clin. Infect. Dis. 30:146-151.
2. Cockcroft, D. W., and M. H. Gault, 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
3. Daly, J. S., G. M. Eiopoulos, E. Reiszner, and R. C. Moellering, Jr. 1988. Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. Antimicrob. Agents Chemother. 21:721-730.
4. Daly, J. S., G. M. Eliopoulos, S. Willey, and R. C. Moellering Jr. 1988. Mechanism of action and in vitro activities of S-6123, a new oxazolidinone compound. Antimicrob. Agents Chemother. 32:1341-1346.
5. Eustice, D. C., P. A. Feldman, and A. M. Slee. 1988. The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis. Biochem. Biophys. Res. Commun. 150:965-971.
6. Eustice, D. C., P. A. Feldman, I. Zajac, and A. M. Slee. 1988. Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimicrob. Agents Chemother. 32:1218-1222.
7. Shinabarger, D. L., K. R. Marotti, R. W. Murray, A. H. Lin, E. P. Melchior, S. M. Swaney, D. S. Dunyak, W. F. Demyan, and J. M. Buysse. 1997. Mechanism of action of oxazolidinones: effect of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother. 41:2132-2136.
8. Sisson, T. L., G. L. Jungbluth, and N. K. Hopkins 1999. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J. Clin. Pharmacol. 39:1277-1282.
9. Sisson, T. L., G. L. Jungbluth, and N. K. Hopkins. 2002. Age and sex effects on the pharmacokinetics of linezolid. Eur. J. Clin. Pharmacol. 57:793-797.
10. 14C] linezolid to healthy human subjects. Drug Metab. Dispos. 29:1136-1145.
11. von Baum, H., J. Schehl, H. K. Geiss, F. Schaefer, et al. 1999. Prevalence of vancomycin-resistant enterococci among children with end-stage renal failure. Clin. Infect. Dis. 29:912-916.
12. Welshman, I. R., T. A. Sisson, G. L. Jungbluth, D. J. Stalker, and N. K. Hopkins. 2001. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm. Drug Dispos. 22:91-97.
13. Zurenko, G. E., B. H. Yagi, R. D. Schaadt, J. W. Allison, J. O. Kilburn, S. E. Glickman, D. K. Hutchinson, M. R. Barbachyn, and S. J. Brickner. 1996. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40:839-845.